InVivoKines™ are a range of recombinant fusion proteins for immunotherapeutic, preclinical & translational in vivo research, developed by AdipoGen.
InVivoKines™ – Proteins with Enhanced Activity & Stability for InVivo Research
Targeting GLP-1 and GIP in Obesity and Type 2 Diabetes Research
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.
New B7 Family Immune Checkpoint Proteins
Recently 5 new B7 family ligands, B7-H3, B7-H4, B7-H5, B7-H6 & B7-H7, were identified, all of them possibly of high interest in immunotherapy research.
HVEM – BTLA – LIGHT – CD160 Network
The checkpoint receptors/ligands system HVEM, LIGHT, CD160 and BTLA (CD272) is part of a complex network of overlapping receptor interactions.
OX40 – OX40L Pathway
OX40 is an activating receptor expressed on the surface of activated cytotoxic T cells & Tregs. OX40 activates & amplifies T cell responses.
TIGIT – CD155 – CD112 – CD226 Network
Tumour cells exploit the dominance of the inhibitory TIGIT pathway to avoid immune-mediated destruction.
LAG-3 – Major Histocompatibility Complex (MHC) – T Cell Receptor (TCR) Pathway
Dual inhibition of LAG-3 and other checkpoint pathways may synergistically increase T cell antitumour activity.
CTLA-4 [CD152] – CD80 – CD86 – CD28 Network
![CTLA-4 [CD152] – CD80 – CD86 – CD28 Network](https://www.caltagmedsystems.co.uk/information/wp-content/uploads/cd28-600x300.png "CTLA-4 [CD152] – CD80 – CD86 – CD28 Network")
Targeting CTLA-4 restores immune response by more accumulation, function & survival of T cells, depletion of Tregs & better antitumour response.
Butyrophilin-like Proteins & Other Immune Checkpoint Proteins
Human Ig superfamily receptor proteins of the structural & functional diverse BTN & BTNL families are potentially important immune modulators.
CD40 – CD40L Pathway
CD40 is a member of the TNF receptor family expressed by APCs and B cells whereas its ligand, CD40L (CD154), is expressed by activated T cells.